Liver expression quantitative trait loci: a foundation for pharmacogenomic research by Dylan M. Glubb et al.
MINI REVIEW ARTICLE
published: 14 August 2012
doi: 10.3389/fgene.2012.00153
Liver expression quantitative trait loci: a foundation for
pharmacogenomic research
Dylan M. Glubb1, Neepa Dholakia2 and Federico Innocenti1,3*
1 Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2 Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
3 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Edited by:
Ulrich M. Zanger, Dr. Margarete
Fischer-Bosch-Institute of Clinical
Pharmacology, Germany
Reviewed by:
Todd Skaar, Indiana University
Medical Center, USA
Rubin Lubomirov, University of
Lausanne, Switzerland
Vishal Lamba, University of
Minnesota, USA
*Correspondence:
Federico Innocenti, Eshelman
School of Pharmacy, Institute for
Pharmacogenomics and
Individualized Therapy, University of
North Carolina at Chapel Hill,
120 Mason Farm Road, Chapel Hill,
NC 27599, USA.
e-mail: innocent@email.unc.edu
Expression quantitative trait loci (eQTL) analysis can provide insights into the genetic
regulation of gene expression at a genomic level and this information is proving extremely
useful in many different areas of research. As a consequence of the role of the liver in
drug metabolism and disposition, the study of eQTLs in primary human liver tissue could
provide a foundation for pharmacogenomics. Thus far, four genome-wide eQTL studies
have been performed using human livers. Many liver eQTLs have been found to be
reproducible and a proportion of these may be specific to the liver. Already these data
have been used to interpret and inform clinic genome-wide association studies, providing
potential mechanistic evidence for clinical associations and identifying genes which may
impact clinical phenotypes. However, the utility of liver eQTL data has not yet been fully
explored or realized in pharmacogenomics. As further liver eQTL research is undertaken,
the genetic regulation of gene expression will become much better characterized and this
knowledge will create a rational basis for the prospective pharmacogenomic study of many
drugs.
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INTRODUCTION
As research has progressed, so has our understanding of how
the genome plays a role in drug disposition and response
via genes related to drug targets or absorption, distribution,
metabolism, and excretion (ADME) (Goldstein et al., 2007).
Indeed, germline human genetic variation is well known to
affect drug disposition and clinical responses to pharmacother-
apy. The Pharmacogenomics Knowledgebase (PharmGKB; www.
pharmgkb.org) curates pharmacogenetic findings from the liter-
ature and, as of May 2012, lists 411 associations between germline
genetic variants and drug-related phenotypes. Only 20% of these
associations can be explained by genetic variation which leads to
distinct protein differences through altered amino acid sequences.
However, genetic variation can impact ADME gene expression
in many different ways, at either mRNA or protein level (Glubb
and Innocenti, 2011). Moreover, transcript levels provide clearly
defined and measurable traits which may act as intermediates for
drug-related phenotypes.
Genetic variants which associate with gene expression are
known as expression quantitative trait loci (eQTLs) and can
be further characterized as cis or trans. cis-eQTLs are located
near the expressed gene, usually defined by an arbitrary distance
(Gilad et al., 2008), whilst trans-eQTLs are located further away,
sometimes on a different chromosome to the expressed gene.
eQTLs can refer to any type of genetic variation but most often
indicate that a single nucleotide polymorphism (SNP) genotype
is associated with the transcript level of a gene. The interro-
gation of SNP genotypes and transcript levels have generally
been performed using oligonucleotide microarray platforms,
enabling the identification of eQTLs through genome-wide analy-
ses (Franke and Jansen, 2009). This linking of gene variation and
genetic expression may clarify the pharmacogenetic significance
of the gene of interest (Li and Deng, 2010) and, thus, eQTLs have
significant potential utility for the study of pharmacogenomics.
Lymphoblastoid cell lines (LCLs) have been the predominant
model for eQTL analyses in humans (Skelly et al., 2009). These
cell lines are derived from B-lymphocytes transformed by the
Epstein-Barr virus (EBV). Although this transformation provides
an immortalized cell line for study, which can be directly exam-
ined in pharmacogenomic studies (Huang et al., 2007a,b; 2008),
there are limitations to their use as non-genetic factors can affect
gene expression (Choy et al., 2008). These factors include the life
history of the human donor, the B-lymphocyte subtype selected,
the EBV titers used for transformation, the culture conditions
in which the LCLs are grown and the intrinsic characteristics
of the cell line. Nevertheless, several studies have translated LCL
eQTL findings in clinical pharmacogenomic studies [reviewed in
(Wheeler and Dolan, 2012)].
In the context of clinical pharmacogenomics, the liver may be
the most relevant tissue in which to perform eQTL analyses. The
liver is the predominant organ in drug elimination, with 75% of
the 200 most widely prescribed drugs being eliminated from the
body through liver metabolism or biliary excretion (Wienkers and
Heath, 2005). Furthermore, a significant number of ADME genes
are strongly expressed in the liver. Schroder et al. defined a list
of 682 ADME genes from various pharmacogenomic resources
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(Schroder et al., 2011) and the expression of 61 of these genes have
been predicted to be liver-specific according to a study of gene
expression in human tissues (Yu et al., 2006). Therefore, eQTLs
of these genes may not be detected in other tissues. In addition,
eQTLs may have effects at the molecular level that are depen-
dent upon the cell or organ in question. In this review, the first
to our knowledge to focus specifically on liver eQTLs, we aim to
show that the liver eQTL knowledge could provide a foundation
to clinical pharmacogenomic research.
LIVER eQTL STUDIES
We are presently in the early stages of liver eQTL research and
only four genome-wide eQTL studies have been reported which
describe the analysis of primary human liver tissue (Table 1).
However, several thousand eQTLs have been identified after cor-
rection for multiple testing and many of the eQTL SNPs (eSNPs)
associate with the expression of ADME genes.
LIVER eQTLS IN PHARMACOGENETIC STUDIES AND CLINICAL
GENOME-WIDE ASSOCIATION STUDIES (GWAS)
ADME genes with liver eQTLs, which pass multiple correction
thresholds in one of the four genome-wide studies, include
COMT, CYP2D6, CYP3A4, CYP3A5, MTHFR, UGT1A1, and
VKORC1 (Table 2). These genes belong to a set of ‘very important
pharmacogenes’ which have been identified by the PharmGKB
resource (http://www.pharmgkb.org/search/browseVip.action?
browseKey=vipGenes). Furthermore, several of these eSNPs
are markers of pharmacogenetic associations (Table 2). These
findings show that liver eQTLs may help explain the associations
of SNPs with clinical phenotypes and also provide a rationale
for using liver eQTL data from relevant genes to select candidate
SNPs for pharmacogenomic study. For example, the three eSNPs
identified in the CYP2D6 gene (Table 2) could conceivably be
used to test associations with pertinent clinical phenotypes of
any of the 46 drugs that, according to PharmGKB curated infor-
mation (http://www.pharmgkb.org/gene/PA128#tabview=tab6&
subtab=21), are metabolized by the CYP2D6 enzyme.
Liver eQTL data can also be used to inform GWAS. GWAS
have identifiedmany SNPswhich are associated with clinical traits
in humans. Typically there is no mechanistic explanation for the
association but eQTLs could help fill this gap in the knowledge.
Amongst the liver eQTL studies, Greenawalt et al. identified 122
eSNPs which were significantly associated, after multiple test cor-
rection, with a clinical phenotype in a GWAS (Greenawalt et al.,
2011) and we found 32 eSNPs that were significant GWAS SNPs
or markers for a GWAS SNP through strong linkage disequilib-
rium (LD) (r2 > 0.8) (Innocenti et al., 2011). In fact, there is
a significant enrichment of eSNPs among SNPs associated with
clinical phenotypes in GWAS (Nicolae et al., 2010). However, a
critical piece of information which is lacking from these reports is
the directionality of the eQTL association (i.e., which allele asso-
ciates with higher/lower transcript levels) and, thus, hypotheses
about the effect of a specific allele cannot be generated.
Another use for eQTLs is in determining which gene a SNP,
associated with a clinical phenotype, may mediate its effect
through as there is often uncertainty about GWAS SNPs located
in intergenic regions. Schadt et al. provide examples of intergenic
eSNPs that were found to associate with type 1 diabetes, coronary
artery disease and LDL cholesterol levels in GWAS (Schadt et al.,
2008). By identifying the gene whose expression the GWAS SNP
associates with, evidence is provided to suggest that the gene may
be a susceptibility factor for the disease.
LIVER eQTL REPRODUCIBILITY
There are many factors related to the liver eQTL studies which
could act as confounders and affect eQTL reproducibility. Firstly,
Table 1 | Summary of human liver eQTL studies.
Category Schadt et al. Innocenti et al. Schroder et al. Greenawalt et al.
Samples in final
analysis (n)
384 206 149 651
Race All Caucasian 183 European American
23 African American
All Caucasian 86% of overall cohort
Caucasian
Nature of liver tissue Postmortem tissue and
resections from donor livers
Postmortem tissue and
resections from donor livers
Normal tissue resected
during surgery for liver
cancer
Tissue from morbidly obese
patients undergoing gastric
bypass
Covariates Age, sex and medical center Age, sex, genetic ancestry,
effects of array hybridization
and oligonucleotide probes,
and surrogate variables
Age, sex, smoking, alcohol
consumption, diagnosis,
C-reactive protein,
cholestatic liver disease and
presurgical medication
Age, sex and medical center
Genotyping platform
(GEO dataset)
Affymetrix 500 k Illumina
650Y (GSE# n/a)
Illumina 610 Quad
(GSE26105)
Illumina HumanHap300
(GSE39036)
Illumina 650Y
(GSE# n/a)
Expression platform
(GEO dataset)
Agilent Custom 44k
(GSE9588)
Agilent 4×44k
(GSE25935)
Illumina HumanWG-6 v2.0
(GSE32504)
Agilent Custom 44k
(GSE24293)
cis-eQTLs (n) 1350 (Bonferroni adjusted)
3210 (FDR<10%)
1787 (BF>5) 1179 (Bonferroni adjustment) 7902 (FDR<10%)
trans-eQTLs (n) 242 (Bonferroni adjustment)
491 (FDR<10%)
353 (BF>5) 47 (Bonferroni adjustment) 785 (FDR<10%)
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Table 2 | Liver eQTLs of PharmGKB ‘very important pharmacogenes’a.
Pharmacogene eSNP eQTL study PharmGKB pharmacogenetic SNPsb
sharing perfect LDc (r2 = 1) with liver eSNP
Pharmacogenetic SNP Related drug(s)
COMT rs174674 Schadt et al. − −
CYP2D6 rs151096 Schadt et al. − −
rs8138080 Schadt et al. − −
rs133337 Innocenti et al. − −
CYP3A4 rs7792939 Greenawalt et al. − −
CYP3A5 rs10242455 Schadt et al.
Schroder et al.
rs4646457
rs776746
Tacrolimus
Cyclosporine
Nevirapine
Paclitaxel
Rosuvastatin
Sirolimus
Sunitinib
Tacrolimus
rs1859690 Schadt et al.
Schroder et al.
rs4646457
rs776746
Tacrolimus
Tacrolimus
Cyclosporine
Nevirapine
Paclitaxel
Rosuvastatin
Sirolimus
Sunitinib
MTHFR rs1801131 Innocenti et al. rs1801131 Methotrexate
Nitrous oxide
UGT1A1 rs2070959 Schroder et al. − –
VKORC1 rs2303222 Innocenti et al. rs2359612
rs8050894
Warfarin
Warfarin
rs10871454 Schroder et al. rs2359612
rs8050894
Warfarin
Warfarin
rs889548 Schroder et al. − −
rs749767 Schroder et al. − −
rs4889606 Schadt et al. − −
aPharmGKB has currently identified 46 genes of particular importance in pharmacogenomics (http://www.pharmgkb.org/search/browseVip.action?browseKey=
vipGenes).
bFrom the PharmGKB curated list of level 1–3 SNP-drug clinical annotations (http://www.pharmgkb.org/search/clinicalAnnotationList.action?evidenceStrength=1).
cLD determined from 1000 Genomes Pilot 1 CEU data using SNAP browser (http://www.broadinstitute.org/mpg/snap/ldsearch.php).
the liver eQTL studies use a variety of tissue sources from
individuals with different ethnic backgrounds (Table 1). Tissue
sources include resections of normal tissue from patients suffer-
ing from liver cancer (Schroder et al., 2011) or morbid obesity
(Greenawalt et al., 2011). Resections of tissue from healthy and
deceased liver donors, who may have undergone multiple phar-
macotherapeutic treatments immediately prior to death, have
also been used (Schadt et al., 2008; Innocenti et al., 2011).
Secondly, different genotyping and gene expression platforms,
and analysis methods were used to generate eQTLs (Table 1).
Furthermore, these studies control for different covariates and
have variable powering due to the number of samples, geno-
types and transcripts interrogated (Table 1). Despite these issues,
there is evidence that a substantial proportion of the cis-eQTL
findings are reproducible. In our liver eQTL study, we attempted
to replicate eQTL findings in two additional datasets, one of
which was a subset of samples from the Schadt et al. study
(Innocenti et al., 2011). 67% of the significant cis-eQTLs (Bayes
factor (BF)>5) replicated in at least one of the additional datasets
(p < 0.05 and concordant effect direction), but this replication
rate dropped to 6% for trans-eQTLs (BF>5) (Innocenti et al.,
2011). Greenawalt et al. examined the reproducibility of their liver
cis-eQTLs (FDR<10%) in the Schadt et al. study, which had used
the same microarray gene expression platform, and found a 66%
overlap (Greenawalt et al., 2011). Using Bonferroni adjusted p-
values, a much more stringent analysis, a comparison between
the Schadt et al. and Schroder et al. studies showed that only
16% of cis-eQTLs replicated and no replication of trans-eQTLs
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(Schroder et al., 2011). Neither of the latter two studies state
whether a concordant effect direction was a criterion for replica-
tion but it appears that liver cis-eQTLs are comparatively repro-
ducible whilst trans-eQTLs are not. This observation may be
partly explained by statistical power. Compared with cis-eQTLs,
trans-eQTLs have a greater multiple test correction burden and,
thus, a trans-eQTL is less likely to achieve statistical significance
in two independent studies.
A salient finding in our study was that the eSNP with the high-
est BF was frequently located immediately upstream or down-
stream of the transcription start site (TSS) of the eQTL gene. Our
group discovered that 75% of cis-eQTLs within 100 kb of the TSS
were found to replicate, compared to 61% of those located more
than 100 kb from the TSS (Innocenti et al., 2011). Furthermore,
Schadt et al. noted in their study that 70% of the cis-eQTLs were
found within 100 kb of the TSS (Schadt et al., 2008). Therefore,
in general, it appears that reproducible liver cis-eQTL SNPs will
be found close to gene TSSs. This suggests that these eSNPs may
directly impact gene transcription by altering gene regulatory
regions.
LIVER eQTL TISSUE SPECIFICITY
To examine tissue specificity of liver eQTLs, Schadt et al. com-
pared their findings with eQTL analyses of human blood and
adipose tissue (Emilsson et al., 2008). Approximately 30% of the
cis-eQTLs identified in these tissues were also detected among
the liver cis-eQTLs (FDR<10%) from their study (Schadt et al.,
2008). Greenawalt et al., examined replication of their liver cis-
eQTLs in adipose tissue from the same cohort of individuals
used for liver eQTL analysis and found 46–48% of the liver cis-
eQTLs replicated at p < 0.05 (Greenawalt et al., 2011). These
observations suggest that some fraction of the genetic control of
gene expression is specific to the liver. Indeed, Greenawalt et al.
found that liver eQTLs, but not eQTLs identified from adipose
tissue, were enriched for the KEGG pathway drug metabolism-
cytochrome P450 genes. Furthermore, of the 11 ADME genes
which had reproducible eQTLs between the Schroder et al. and
Schadt et al. studies (Schadt et al., 2008; Schroder et al., 2011),
CYP3A5, DHRS2 and SLC22A3 have been predicted to have
liver-specific expression (Yu et al., 2006).
CORRELATION OF LIVER eQTLS AND P450 ENZYME ACTIVITY
Gene transcript levels are a useful intermediate phenotype to
study but measurements of protein levels or enzyme activity may
provide a more informative phenotype for pharmacogenomics.
One of the advantages of the liver eQTL model is that subcellu-
lar fractions can be generated from the liver, allowing proteomic
and biochemistry studies to be integrated with genomic and tran-
scriptomic data from the same tissue. For example, Yang et al.
examined the enzyme activity of eight P450 proteins using liver
microsomal samples derived from the same cohort as Schadt
et al. (2008), and found that the activities of the CYP450s were
positively correlated with mRNA transcript levels after adjust-
ing transcript and activity levels for age, sex and study site
(Yang et al., 2010). Transcript levels explained 10–30% of the
variance in enzyme activity, thus, indicating that other biolog-
ical factors, such as post-translational mechanisms, may also
impact on activity levels. Fifty four enzyme activity QTLs (aQTLs)
were identified for the eight P450 proteins: 24 SNPs were trans-
aQTLs and 30 cis-aQTLs (FDR<10%) (Yang et al., 2010). The
cis-aQTL SNPs were all associated with CYP2D6 enzyme activ-
ity and 29 of these were found to be also cis-eSNPs of CYP2D6
(FDR<10%).
WEB-BASED LIVER eQTL DATA RESOURCES
The Gene Expression Omnibus (GEO) repository contains data
from all the human liver eQTL studies (Table 1), although
genotypes from the Schadt et al. and Greenawalt et al. stud-
ies are not available. The data cannot be easily interrogated
and, thus, we plan to upload the liver eQTL findings of our
study to the web-based SNP and CNV Association (SCAN)
database (Gamazon et al., 2010). The results of the Schadt
et al. study are already available through the Genotype-Tissue
Expression (GTEx) eQTL browser (http://www.ncbi.nlm.nih.
gov/gtex/GTEX2/gtex.cgi), and can be queried by gene or SNP
and filtered by p-value or r2. The GTEx browser provides fur-
ther useful information by annotating corresponding eSNPs with
significant findings from GWAS.
FUTURE DIRECTIONS
CNVs
Single nucleotide base changes are the most common but not the
only germline genetic variation present in the human genome. A
study of genetic variation in eight individuals identified four mil-
lion SNPs, ∼800,000 insertion/deletions (>1 – 100 bp) and 1695
structural (>6 kb) variants, also known as copy number variants
(CNVs) (Kidd et al., 2008). Although CNVs are much fewer in
number than SNPs, their potential to impact on gene expression
is greater due to their size and ability to increase gene copy num-
ber or ablate the transcriptional unit. Indeed, SNPs which are
in strong LD (r2 = 0.8) with CNVs are more likely to be LCL
eQTLs and associated with the expression of more than one gene
(Gamazon et al., 2011). Moreover, the importance of CNVs in
pharmacogenetics is already well known. CNVs with functional
effects on enzyme activity of proteins (e.g., CYP2D6, GSTM1 and
GSTT1) have been observed to associate with drug efficacy and
toxicity (He et al., 2011). It is likely that these CNVsmay be eQTLs
and, thus, there is a great need for liver CNV eQTL analyses to be
carried out in the future.
NEXT-GENERATIONSEQUENCING
Previous liver eQTL studies have interrogated genetic variation
and gene expression at the genome level. However, due to the
limitations of the oligonucleotide genotyping and gene expres-
sion microarray platforms, this corresponds only to a fraction of
human genetic variation and does not encompass all transcript
splice variants or gene isoforms.
Genotype imputation can be performed using genotype data
from studies like HapMap or 1000 Genomes Project to greatly
increase the number of genotypes interrogated through oligonu-
cleotide genotyping platforms. Indeed, in our liver eQTL study
we imputed genotypes from HapMap to generate more than two
million genotypes (Innocenti et al., 2011). While still relatively
expensive, next-generation sequencing has advanced to the point
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where it is becoming feasible to perform whole genome sequenc-
ing of DNA and mRNA to comprehensively characterize genetic
variation and the entire transcriptome in a relatively large number
of samples.
Although there is high correlation between transcript levels
quantitated by RNA-seq and microarrays (Pickrell et al., 2010),
RNA-seq provides a greater resolution which leads to detection
of more eQTLs (Montgomery et al., 2010). The RNA-seq (next
generation sequencing of mRNA) approach has other advan-
tages over oligonucleotide expression arrays e.g., no saturation of
intensity signal for high abundance transcripts and the ability to
quantify allele-specific expression (Majewski and Pastinen, 2011).
Additionally, RNA-seq can identify splicing QTLs which may not
affect overall gene expression but alter transcript isoform levels
(Pickrell et al., 2010).
IDENTIFICATION OF FUNCTIONAL eSNPs
eQTL analyses are informative but they cannot definitively iden-
tify the causative SNPs that affect gene expression. Due to LD,
many eSNPs can represent the same causative genetic variant.
Various approaches can be used to identify functional genetic
variants which generate the eQTL signal. Reporter gene assays are
useful in determining whether eSNPs in promoter, 5′UTR, 3′UTR
and intronic regions have functional effects on gene expression
(Innocenti et al., 2011). However, this technique cannot be easily
applied in a high-throughput fashion and the effects of SNPs in
coding regions are generally not amenable to testing.
Bioinformatic analyses may help to narrow the number of
putatively causative SNPs, by identifying eSNPs which are located
in functional genomic elements such as those defined by the
Encyclopedia of DNA Elements (ENCODE) Project (Myers et al.,
2011). Indeed, a study of LCL eQTLs found that 40% of the
eSNPswere located in open chromatin regions and sites of DNaseI
hypersensitivity or histone modification. Furthermore, SNPs in
DNaseI hypersensitivity sites were four-fold more likely to asso-
ciate with transcript levels compared with other SNPs (Gaffney
et al., 2012). This epigenetic, and other regulatory, informa-
tion can be combined with eQTL data to create a model which
ranks eSNPs on their potential to affect gene expression (Gaffney
et al., 2012). This approach has not yet been applied to a study
of liver eQTLs but could prove extremely useful in identifying
pharmacogenetic variants.
EPISTATIC eQTL INTERACTIONS
eQTL analyses generally examine only the effects of a single
genetic locus on gene expression. However, it is possible that
interactions of cis- and trans-eQTLs contribute to the regulation
of gene expression. Indeed, 15% of transcripts were found to be
regulated by a cis-trans eQTL interaction in a study of HapMap
LCLs and the vast majority of the eSNPs were not significantly
associated with gene expression in a single locus analysis (Becker
et al., 2012). Therefore, important information may be lost by not
considering these eQTL interactions and this approach could be
used to detect epistatic pharmacogenetic variants which may not
otherwise be identified.
LIVER PROTEIN QTLs
The Yang et al. study (Yang et al., 2010) correlating liver eQTLs
and P450 enzyme activity highlights the need for liver protein
QTL analyses to characterize the genetic regulation of protein
expression. High-throughput proteome-wide quantification of
protein expression is much more problematic and less straight-
forward than that for transcriptome quantification. Liquid
chromatography-tandem mass spectrometry (LC-MS/MS) tech-
niques are providing a way forward but, currently, the best
approach for sensitive and accurate protein quantitation may be
to carry out targeted proteomic studies (Kline et al., 2009). For
example, targeted LC-MS/MS analysis of several UGT1A isoforms
has been successfully performed in human liver microsomes
(Harbourt et al., 2012).
CONCLUSION
There is a strong rationale for using findings from human liver
eQTL studies as a knowledge base to inform and guide clinical
pharmacogenomic studies. Liver eQTL analyses provide insights
into the genetic regulation of ADME genes which may not be
obtained from other tissues and identifies eQTLs which are
reproducible and unique to the liver. Moreover, liver eQTL data
can help explain previously identified pharmacogenomic associ-
ations and provides candidates for prospective clinical study. In
the future, the integration of epistatic, epigenetic, CNV, next-
generation sequencing, bioinformatic, and protein analyses will
generate a truly comprehensive map of the genetic regulation of
gene expression in the liver which is certain to profoundly impact
pharmacogenomics.
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